Could a higher dose of urokinase save more brains after stroke?

NCT ID NCT07047326

Recruiting now Disease control Sponsor: Capital Medical University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 15, 2026 · Updated 3 times

Summary

This study tests increasing doses of the clot-busting drug urokinase in 24 people with acute ischemic stroke, given within 6 hours of symptoms. The goal is to find the highest safe dose and develop a weight-based dosing plan. Researchers will watch closely for bleeding complications to balance safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: urokinase
What this could lead to: If successful, this could establish a safer, more effective weight-based dosing regimen for urokinase, potentially improving stroke outcomes at a lower cost than current alternatives.
What could go wrong: This is a very early, small safety study with only 24 participants. The main risk is bleeding in the brain, and higher doses may not prove safer or more effective than standard care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE

Contacts and locations

Locations

Handan Central Hospital
RECRUITING

Handan, Hebei, 056002, China
Xuanwu Hospital, Capital Medical University
RECRUITING

Beijing, Beijing Municipality, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.